Israel VC Backs MiNA's Novel SaRNAs In Cancer, And Add-On Therapy Areas
Lead Compound Heading For Phase II
Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.
